EDSA (Edesa Biotech) Total Receivables: $0.22 Mil (As of Mar. 2026)


EDSA Edesa Biotech Inc EDSA
26 GF Score
Price $7.45
! 2 Warning Signs
View Full Analysis

What is Edesa Biotech Total Receivables?

Edesa Biotech EDSA -3.23% 26 Total Receivables is $0.22 Mil as of Mar. 2026. GuruFocus rates EDSA with a GF Score™ of 26/100. The stock has 2 warning signs investors should review.

Edesa Biotech's Total Receivables for the quarter that ended in Mar. 2026 was $0.22 Mil.

Edesa Biotech Total Receivables Related Terms

Edesa Biotech Total Receivables Historical Data

* Premium members only.

The historical data trend for Edesa Biotech's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Edesa Biotech Total Receivables Chart

Edesa Biotech Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.30 1.26 0.63 0.27 0.64

Edesa Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.38 0.29 0.64 0.43 0.22
EDSA
26GF Score
Edesa Biotech Inc EDSA
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Edesa Biotech Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of $0.22 Mil mean?
Edesa Biotech (EDSA) has a Total Receivables of $0.22 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Edesa Biotech and its competitors.
Is Edesa Biotech's Total Receivables too high?
Edesa Biotech's current Total Receivables is $0.22 Mil. Overall, Edesa Biotech has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Edesa Biotech's Total Receivables compare to ACET and HRTX?
Edesa Biotech's Total Receivables of $0.22 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Edesa Biotech and its competitors. Edesa Biotech's current Total Receivables is $0.22 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edesa Biotech stock overvalued right now?
Edesa Biotech (EDSA) has a current Total Receivables of $0.22 Mil. The current Total Receivables is $0.22 Mil. Edesa Biotech's overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Edesa Biotech (EDSA), the current Total Receivables is $0.22 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Edesa Biotech Business Description

Address 100 Spy Court, Markham, ON, CAN, L3R 5H6
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
26GF Score

Get the complete analysis for EDSA

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.45
Price